Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

China Pharma Ups Q3 Revenue Guidance

publication date: Sep 18, 2008

China Pharma Holdings forecast that its Q3 revenues would grow between 40% and 45% over the year-previous figures. That would be a better performance than Q2, during which revenues climbed 32%. In the first quarter, however, China Pharma reported a 60% jump in its top line. The single analyst who follows China Pharma is predicting a 33% gain in Q3. An increase to 40% growth would take the company’s revenues $500,000 higher to approximately $11.5 million. More details...

Stock Symbol: (OTCBB: CPHI)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital